News

TheraCryf plc is an LSE AIM listed biotechnology company developing new medicines for addiction and other disorders of the brain, areas of significant unmet medical need within central nervous system disorders.

The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026.

TheraCryf also has a dopamine transporter modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy. The Group also has a legacy, grant-funded, oncology programme in glioblastoma with SFX-01.

TheraCryf operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering with larger pharmaceutical or biotechnology companies.

On 20 August 2026, the Company announced that it proposed to raise a total of approximately £1.05 million by way of a placing of 416,388,888 placing shares and subscription for 166,944,440 subscription shares, with existing and new investors at an issue price of 0.18 pence per new ordinary share.

Placing and subscription

Following the General Meeting held on 7 September 2026, the Company further announced that the fundraising was approved by Shareholders.

The Perivan shareholder communications team was delighted to work with Osborne Clarke who acted as Legal Adviser to TheraCryf on the documentation which was successfully completed and posted to qualifying shareholders on 20 August 2026.

Perivan specialises in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and is a market leader in the production of documentation relating to corporate finance transactions.